597 Vaccine antigen-specific T cell responses persisted several years after initial vaccination in patients with prostate cancer who re-enrolled to a subsequent study involving multiepitope vaccination
Hoyoung Maeng(National Cancer Institute), Jay A. Berzofsky(National Cancer Institute), Seth M. Steinberg(National Cancer Institute), William E. Becker(National Institutes of Health), Ira Pastan(National Institutes of Health), Hyoyoung Choo‐Wosoba(National Institutes of Health), Purevdorj B. Olkhanud(National Institutes of Health), Brittni N. Moore(National Institutes of Health), David Stroncek(National Institutes of Health), Katherine McKinnon(National Institutes of Health), Lauren V. Wood(National Cancer Institute)
Cited by 0
Related Papers
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|312